Cost-Effectiveness Measures, Methods, and Policy Implications From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia
Salesof atypical antipsychotics have expanded rapidly as their use for treatment ofschizophrenia and other illnesses has increased. The CATIE trial was designedto evaluate the cost-effectiveness of these medications. Cost-effectivenessanal’ ‹ysis in CATIE examined the benefits and costs of treatments and attemptedto determine whether one treatment would result in better outcomes and lowercosts than another one. While the data from CATIE on cost-effectiveness havenot been analyzed yet, it is still possible to consider the potential implicationsof the analysis, including how the roles of researchers and stakeholders shouldbe considered in deciding optimal clinical practices and public policies.